Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

TELMISARTAN AUROVITAS 40 MG COMPRIMIDOS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/TELMISARTAN AUROVITAS 40 MG COMPRIMIDOS EFG

Approved

STANDARD

TELMISARTAN AUROVITAS 40 MG COMPRIMIDOS EFG

Aurovitas Spain, S.A.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Mar 31, 2022
Approval ID: f1a829dca67d2c26
Company: Aurovitas Spain, S.A.U.
Type: Standard

Approval Details

Approval Id: f1a829dca67d2c26
Drug Cima Aemps Name: TELMISARTAN AUROVITAS 40 MG COMPRIMIDOS EFG
Register Number: 86721
Holder Company Name: Aurovitas Spain, S.A.U.
Marketing Company Name: Aurovitas Spain, S.A.U.
Authorization Date: 2022-03-31
Dosage Form: COMPRIMIDO
Dose: 40 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Aurovitas Spain, S.A.U.

Active Ingredients

TELMISARTAN

40 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Mar 31, 2022

Approval ID

f1a829dca67d2c26

Type

Standard

Back to CIMA-AEMPS Approvals